Cargando…
ISCOMATRIX vaccines mediate CD8(+) T-cell cross-priming by a MyD88-dependent signaling pathway
Generating a cytotoxic CD8(+) T-cell response that can eradicate malignant cells is the primary objective of cancer vaccine strategies. In this study we have characterized the innate and adaptive immune response to the ISCOMATRIX adjuvant, and the ability of vaccine antigens formulated with this adj...
Autores principales: | Wilson, Nicholas S, Yang, Becky, Morelli, Adriana Baz, Koernig, Sandra, Yang, Annie, Loeser, Stefanie, Airey, Denise, Provan, Larissa, Hass, Phil, Braley, Hal, Couto, Suzana, Drane, Debbie, Boyle, Jeff, Belz, Gabrielle T, Ashkenazi, Avi, Maraskovsky, Eugene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365289/ https://www.ncbi.nlm.nih.gov/pubmed/21894173 http://dx.doi.org/10.1038/icb.2011.71 |
Ejemplares similares
-
Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer
por: Barr, Adele M., et al.
Publicado: (2020) -
CpG ODN and ISCOMATRIX Adjuvant: A Synergistic Adjuvant Combination Inducing Strong T-Cell IFN-γ Responses
por: McCluskie, Michael J., et al.
Publicado: (2013) -
The CD8(+) T Cell-Mediated Immunity Induced by HPV-E6 Uploaded in Engineered Exosomes Is Improved by ISCOMATRIX(TM) Adjuvant
por: Manfredi, Francesco, et al.
Publicado: (2016) -
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma
por: Cebon, Jonathan S, et al.
Publicado: (2020) -
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
por: Munshi, Manit, et al.
Publicado: (2020)